<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490841</url>
  </required_header>
  <id_info>
    <org_study_id>05-102</org_study_id>
    <nct_id>NCT00490841</nct_id>
  </id_info>
  <brief_title>The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis</brief_title>
  <acronym>HERCULES</acronym>
  <official_title>A Clinical Trial to Assess the Safety and Efficacy of the RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Suboptimal Post-procedural Percutaneous Transluminal Angioplasty (PTA) in de Novo or Restenotic Renal Artery Stenoses in Patients With Uncontrolled Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Herculink Elite Renal Stent System is
      safe and effective in the treatment of renal artery stenosis in patients with less than
      optimal angioplasty results and uncontrolled hypertension.

      CAUTION: The Herculink Elite Renal Stent System Is An Investigational Device. Limited by
      Federal (U.S.) Law to Investigational Use Only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the
      treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of
      atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled
      hypertension.

      CAUTION: The Herculink Elite Renal Stent System Is An Investigational Device. Limited by
      Federal (U.S.) Law to Investigational Use Only.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binary Restenosis Rate</measure>
    <time_frame>9 months</time_frame>
    <description>Determined by duplex ultrasound or angiogram. Reported as the percentage of participants with occurance of binary restenosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death for Any Reason</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ipsilateral Nephrectomy</measure>
    <time_frame>30 days</time_frame>
    <description>Ipsilateral: Situated on or affecting the same side as treated. Nephrectomy: Removal of the affected kidney</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embolic Events Resulting in Kidney Damage</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of participants with an embolic event resulting in kidney damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Rate of Clinically Indicated Target Lesion Revascularization (TLR)</measure>
    <time_frame>9 months</time_frame>
    <description>Event Free percentage: Defined as percentage of participants free from this event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9 Month Blood Pressure (Systolic)</measure>
    <time_frame>Baseline (Pre-Procedure) and 9 months</time_frame>
    <description>As compared to baseline (pre-procedure). Blood pressure measurements at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9 Month Blood Pressure (Diastolic)</measure>
    <time_frame>9 months and baseline</time_frame>
    <description>As compared to baseline. See Population description.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Device Success</measure>
    <time_frame>From beginning of index procedure to end of index proceedure.</time_frame>
    <description>Acute device success is defined as, on a per device basis, the achievement of successful delivery of the assigned device(s)as intended to the designated location.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Procedure Success</measure>
    <time_frame>From beginning of index proceedure to end of index proceedure.</time_frame>
    <description>Attainment of a final result of &lt; 30% residual stenosis, as determined by the Angiographic Core Lab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Clinical Success</measure>
    <time_frame>From beginning of index proceedure to end of index proceedure.</time_frame>
    <description>Procedure success without Major Adverse Events (MAE)or access site event requiring surgical or percutaneous intervention prior to hospital discharge.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>9 months</time_frame>
    <description>Defined as &lt;60% stenosis without prior re-intervention, as determined by duplex ultrasound or angiogram.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency Rate of &lt;60% Stenosis of the Target Lesion</measure>
    <time_frame>9 months</time_frame>
    <description>As determined by duplex ultrasound or angiography regardless of PTA, stenting, or bypass since index procedure. Rate reported as a percentage of participants with this condition.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9 Month Anti-hypertensive Medication In-take, 1 Medication</measure>
    <time_frame>9 months</time_frame>
    <description>Number of Anti-Hypertensive Medications taken-baseline compared to follow up, Per Subject Analysis (Intent-to-Treat Population), reported as the percentage of participants using the number of medications indicated.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9 Month Anti-hypertensive Medication In-take, 2 Medications</measure>
    <time_frame>9 months</time_frame>
    <description>Number of Anti-Hypertensive Medications taken-baseline compared to follow up, Per Subject Analysis (Intent-to-Treat Population)), reported as the percentage of participants using the number of medications indicated.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9 Month Anti-hypertensive Medication In-take, 3 Medications</measure>
    <time_frame>9 months</time_frame>
    <description>Number of Anti-Hypertensive Medications taken-baseline compared to follow up, Per Subject Analysis (Intent-to-Treat Population)), reported as the percentage of participants using the number of medications indicated.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9 mo in Anti-hypertensive Medication In-take, â‰¥ 4 Medications</measure>
    <time_frame>9 months</time_frame>
    <description>Number of Anti-Hypertensive Medications taken at follow up compared to baseline, Per Subject Analysis (Intent-to-Treat Population)), reported as the percentage of participants using the number of medications indicated.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function (Measured by sCr)</measure>
    <time_frame>9 months</time_frame>
    <description>sCR= Serum Creatinine, per subject analysis. ITT. Renal function (measured by sCr) @ baseline: 1.2mg/dL (1.2, 1.3).
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Renal Artery Obstruction</condition>
  <condition>Hypertension, Renal</condition>
  <arm_group>
    <arm_group_label>RX Herculink Elite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Herculink Elite Renal Stent System</intervention_name>
    <description>This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.</description>
    <arm_group_label>RX Herculink Elite</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Clinical Inclusion Criteria:

          -  Subject is â‰¥18 years of age.

          -  Subject and subject's physician agree to have the subject return for all required
             contact following study enrollment.

          -  Subject has been informed of the nature of the study, and has provided written
             informed consent, approved by the appropriate Institutional Review Board (IRB) of the
             respective clinical site.

          -  Subject is a candidate for renal artery stenting.

          -  Subject has uncontrolled systolic hypertension (systolic Blood Pressure[SBP] â‰¥140
             mmHg), or uncontrolled diastolic hypertension (diastolic BP [DBP] â‰¥90 mmHg), or a
             combination of both in the presence of at least two (2) or more antihypertensive
             medications.

          -  Subject has a baseline serum Creatinine of &lt;2.5mg/dl

        Angiographic Inclusion Criteria

          -  Subject has either unilateral or bilateral de novo or restenotic after Percutaneous
             Transluminal Angioplasty (PTA) (in-stent restenosis excluded) atherosclerotic
             lesion(s). If bilateral lesions are to be treated, the most severe lesion must be
             successfully treated without complications before progressing to treat the second
             lesion. Treatment of bilateral lesions is to occur in the same procedural event.

          -  Renal stenosis must be visually estimated to be â‰¥60% by angiography.

          -  Subject has a suboptimal PTA result, defined as one of the following:

               -  â‰¥50% residual stenosis

               -  10 mm Hg mean gradient or 20 mm Hg peak systolic gradient across the target
                  lesion

               -  A flow-limiting dissection (NHLBI grade D) or TIMI flow &lt;3

          -  Renal stenosis must be visually estimated to be within 10 mm of the aortic renal
             border by angiography.

          -  Target vessel reference diameter must be visually estimated to be â‰¥4mm and â‰¤7mm by
             angiography

          -  Target lesion length must be visually estimated to be â‰¤15mm (including dissection) by
             angiography.

          -  Expected ability to deliver the stent to the lesion (absence of excessive tortuosity
             or calcification).

          -  Expected ability to fully expand the stent.

        Clinical Exclusion Criteria

          -  Subject has known hypersensitivity or contraindication to cobalt chromium or standard
             intraprocedure anticoagulant(s); subject has sensitivity to contrast which cannot be
             adequately pre-treated with medication.

          -  Subject has known allergy or contraindication to clopidogrel (Plavix) or aspirin.

          -  Subject has known bleeding disorder or hypercoagulable disorder, or will refuse blood
             transfusions.

          -  Subject has suffered a gastrointestinal (GI) bleed within 30 days before the index
             procedure that would interfere with antiplatelet therapy.

          -  Subject has renal insufficiency defined as serum Creatinine &gt;2.5 mg/dl.

          -  Subject has any immunosuppressive disorder, access site infection, or acute systemic
             infection due to any cause.

          -  Subject has other medical illnesses (e.g., cancer, end-stage congestive heart failure)
             that may cause the subject to be non-compliant with protocol requirements, confound
             the data interpretation, or is associated with a life expectancy of less than three
             years.

          -  Subject has any medical illnesses that would make them unlikely to respond to
             treatment (e.g., sickle cell nephropathy/sickle cell disease, scleroderma, arteriolar
             nephrosclerosis, hemolytic-uremic syndrome and vasculitis).

          -  Subject has had a Q-wave MI within 30 days before index procedure.

          -  Subject has had a stroke or TIA within 30 days before index procedure.

          -  Subject has a history of congestive heart failure and has a previously documented LVEF
             â‰¤25%.

          -  Subject is normotensive or has adequate control of hypertension (SBP &lt;140 mmHg and DBP
             &lt;90 mm Hg) utilizing diet control and/or medication regimen involving only one
             antihypertensive medication.

          -  Subject has acute thrombophlebitis or deep vein thrombosis.

          -  Subject is actively participating in another drug or device trial and has not
             completed the required protocol follow-up period. Subject may be enrolled only once in
             this study (Protocol # 05-102) and may not participate in any other clinical trial
             during the follow-up period.

          -  Subject is unable to understand and cooperate with study procedures or provide
             informed consent.

          -  Subject is unable to return for follow-up visits (distance, etc).

          -  Subject is pregnant.

          -  Subject has undergone vascular surgery (CABG, AAA repair, AF bypass) and has not fully
             recovered from the effects of surgery (&lt;3 months).

          -  Subject has planned staged treatment of bilateral renal artery stenosis.

          -  Subject has had prior surgical intervention to the target artery, or has undergone
             previous stent placement in the target lesion.

          -  Target lesion is located in a transplanted kidney.

          -  Kidney to be treated is &lt;8 cm as determined by duplex ultrasound report, CTA report,
             or MRA report within 180 days before procedure. If kidney size is documented by more
             than one method, e.g. CTA and ultrasound, and one of the methods is duplex ultrasound,
             the kidney size as documented by duplex ultrasound shall be used to determine study
             eligibility.

          -  Subject has planned additional ancillary procedure(s) during renal stenting procedure.

        Angiographic Exclusion Criteria

          -  Subject has a lesion segment, including dissection, &gt;15 mm in length.

          -  Requirement for &gt;1 stent to treat full length of lesion and dissection.

          -  Target lesion has a total (100%) occlusion.

          -  Evidence of thrombus or mobile filling defect in the target lesion or vessel.

          -  Subject has co-existing aneurysmal or occlusive disease of the abdominal aorta
             requiring surgical reconstruction during the follow-up period.

          -  Target lesion is non-atherosclerotic (fibromuscular dysplasia).

          -  Subject artery has patent bifurcation within 10 mm of ostium that might be covered by
             placement of a stent.

          -  The target lesion is within the artery of a solitary functioning kidney or, the
             subject has a contralateral totally occluded renal artery.

          -  For planned treatment of bilateral lesions: the more critical lesion, i.e. lesion with
             the greater stenosis (which should be treated first), is either treated unsuccessfully
             or requires a bailout procedure. (NOTE: Less critical lesion is excluded at this
             point.)

          -  Subject has any condition that precludes proper angiographic assessment or makes
             percutaneous arterial access unsafe.

          -  The target lesion is densely calcified and will not yield during balloon dilation.

          -  Subject has had recent change in renal function after unrelated catheter or surgical
             procedure with the clinical stigmata of atheroemboli syndrome (i.e., livedo
             reticularis: non-occlusive mesenteric ischemia; digital gangrene; progressive renal
             insufficiency without other identifiable etiology).

          -  Subject has an accessory renal artery that has &gt;50% stenosis. Accessory renal arteries
             may not be stented as part of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Bates, MD</last_name>
    <role>Study Director</role>
    <affiliation>CAMC Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Textor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Jaff, DO</last_name>
    <role>Study Director</role>
    <affiliation>Vascular Diagnostic Laboratory</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Sullivan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Heart Hospital of SD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Blum, MD</last_name>
    <role>Study Director</role>
    <affiliation>Midwest Heart Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abbott Vascular</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2007</study_first_submitted>
  <study_first_submitted_qc>June 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2007</study_first_posted>
  <results_first_submitted>September 6, 2011</results_first_submitted>
  <results_first_submitted_qc>December 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2012</results_first_posted>
  <disposition_first_submitted>March 21, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>March 21, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 1, 2011</disposition_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Renal Artery Obstruction</mesh_term>
    <mesh_term>Hypertension, Renal</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects admitted for percutaneous renal artery revascularization were considered for enrollment at sites throughout the USA. Dates of enrollment: August 31, 2007 through October 02, 2009.</recruitment_details>
      <pre_assignment_details>Subjects required to have documented uncontrolled hypertension (SBP at least 140 mmHg or DBP at least 90 mmHg, or both) in the presence of at least two (2) or more antihypertensive medications, all clinical eligibility criteria had to have been met and sujects had to sign the informed consent form. Intent to treat (ITT) population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RX Herculink Elite</title>
          <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>30 day f/u, only non-study stent used</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RX Herculink Elite</title>
          <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="202"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.1" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Binary Restenosis Rate</title>
        <description>Determined by duplex ultrasound or angiogram. Reported as the percentage of participants with occurance of binary restenosis.</description>
        <time_frame>9 months</time_frame>
        <population>Subject total reflects those who were evaluable at the time of analysis. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician. Only a certain number of patients were required to have angiographic follow-up to provide this endpoint information.</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>Binary Restenosis Rate</title>
          <description>Determined by duplex ultrasound or angiogram. Reported as the percentage of participants with occurance of binary restenosis.</description>
          <population>Subject total reflects those who were evaluable at the time of analysis. The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician. Only a certain number of patients were required to have angiographic follow-up to provide this endpoint information.</population>
          <units>Percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" upper_limit="14.7">One-sided confidence interval was computed for this endpoint, lower bound is not provided.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>objective is to demonstrate the binary restenosis rate at 9 months is &lt; 28.6% OPC. Assumptions for the primary endpoint analysis:
H0: Restenosis Rate â‰¥ 28.6%
HA: Restenosis Rate &lt; 28.6%
Assumed binary restenosis rate = 20%
Power = 80%
One-sided type I error = 5%
With the above assumptions, 161 samples would be required. To account for approximately 20% lost to followâ€“up rate, 202 subjects will be enrolled in the study. The sample size calculation was performed using PASS 2005.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>1-sided exact binomial test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death for Any Reason</title>
        <time_frame>30 days</time_frame>
        <population>Non-Hierarchical Subject Counts, Per Subject Analysis (Intent-to-Treat Population). The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>Death for Any Reason</title>
          <population>Non-Hierarchical Subject Counts, Per Subject Analysis (Intent-to-Treat Population). The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ipsilateral Nephrectomy</title>
        <description>Ipsilateral: Situated on or affecting the same side as treated. Nephrectomy: Removal of the affected kidney</description>
        <time_frame>30 days</time_frame>
        <population>intention to treat (ITT). The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>Subjects recieving the RX Herculink Elite</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Nephrectomy</title>
          <description>Ipsilateral: Situated on or affecting the same side as treated. Nephrectomy: Removal of the affected kidney</description>
          <population>intention to treat (ITT). The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Embolic Events Resulting in Kidney Damage</title>
        <description>Percentage of participants with an embolic event resulting in kidney damage.</description>
        <time_frame>30 days</time_frame>
        <population>The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>Subjects recieving the RX Herculink Elite</description>
          </group>
        </group_list>
        <measure>
          <title>Embolic Events Resulting in Kidney Damage</title>
          <description>Percentage of participants with an embolic event resulting in kidney damage.</description>
          <population>The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.1" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Free Rate of Clinically Indicated Target Lesion Revascularization (TLR)</title>
        <description>Event Free percentage: Defined as percentage of participants free from this event.</description>
        <time_frame>9 months</time_frame>
        <population>The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>Subjects recieving the RX Herculink Elite</description>
          </group>
        </group_list>
        <measure>
          <title>Event Free Rate of Clinically Indicated Target Lesion Revascularization (TLR)</title>
          <description>Event Free percentage: Defined as percentage of participants free from this event.</description>
          <population>The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>Event Free Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9 Month Blood Pressure (Systolic)</title>
        <description>As compared to baseline (pre-procedure). Blood pressure measurements at 9 months.</description>
        <time_frame>Baseline (Pre-Procedure) and 9 months</time_frame>
        <population>The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>9 Month Blood Pressure (Systolic)</title>
          <description>As compared to baseline (pre-procedure). Blood pressure measurements at 9 months.</description>
          <population>The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9 month Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.3" lower_limit="142.1" upper_limit="148.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Pre-Procedure) Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.3" lower_limit="159.8" upper_limit="164.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9 Month Blood Pressure (Diastolic)</title>
        <description>As compared to baseline. See Population description.</description>
        <time_frame>9 months and baseline</time_frame>
        <population>The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>9 Month Blood Pressure (Diastolic)</title>
          <description>As compared to baseline. See Population description.</description>
          <population>The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9 month Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" lower_limit="73.6" upper_limit="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7" lower_limit="76.1" upper_limit="79.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Device Success</title>
        <description>Acute device success is defined as, on a per device basis, the achievement of successful delivery of the assigned device(s)as intended to the designated location.</description>
        <time_frame>From beginning of index procedure to end of index proceedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Device Success</title>
          <description>Acute device success is defined as, on a per device basis, the achievement of successful delivery of the assigned device(s)as intended to the designated location.</description>
          <units>percentage of devices</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Devices</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="92.7" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Procedure Success</title>
        <description>Attainment of a final result of &lt; 30% residual stenosis, as determined by the Angiographic Core Lab.</description>
        <time_frame>From beginning of index proceedure to end of index proceedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Procedure Success</title>
          <description>Attainment of a final result of &lt; 30% residual stenosis, as determined by the Angiographic Core Lab.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="97.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Clinical Success</title>
        <description>Procedure success without Major Adverse Events (MAE)or access site event requiring surgical or percutaneous intervention prior to hospital discharge.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
        <time_frame>From beginning of index proceedure to end of index proceedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Clinical Success</title>
          <description>Procedure success without Major Adverse Events (MAE)or access site event requiring surgical or percutaneous intervention prior to hospital discharge.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Patency</title>
        <description>Defined as &lt;60% stenosis without prior re-intervention, as determined by duplex ultrasound or angiogram.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
        <time_frame>9 months</time_frame>
        <population>Subject total reflects those who were evaluable at the time of analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency</title>
          <description>Defined as &lt;60% stenosis without prior re-intervention, as determined by duplex ultrasound or angiogram.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
          <population>Subject total reflects those who were evaluable at the time of analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="82.9" upper_limit="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Patency Rate of &lt;60% Stenosis of the Target Lesion</title>
        <description>As determined by duplex ultrasound or angiography regardless of PTA, stenting, or bypass since index procedure. Rate reported as a percentage of participants with this condition.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
        <time_frame>9 months</time_frame>
        <population>Subject total reflects those who were evaluable at the time of analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Patency Rate of &lt;60% Stenosis of the Target Lesion</title>
          <description>As determined by duplex ultrasound or angiography regardless of PTA, stenting, or bypass since index procedure. Rate reported as a percentage of participants with this condition.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
          <population>Subject total reflects those who were evaluable at the time of analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2" lower_limit="91.3" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9 Month Anti-hypertensive Medication In-take, 1 Medication</title>
        <description>Number of Anti-Hypertensive Medications taken-baseline compared to follow up, Per Subject Analysis (Intent-to-Treat Population), reported as the percentage of participants using the number of medications indicated.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
        <time_frame>9 months</time_frame>
        <population>Patients with baseline Anti-Hypertensive medication intake equal to 1 medication: 0.5%</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>9 Month Anti-hypertensive Medication In-take, 1 Medication</title>
          <description>Number of Anti-Hypertensive Medications taken-baseline compared to follow up, Per Subject Analysis (Intent-to-Treat Population), reported as the percentage of participants using the number of medications indicated.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
          <population>Patients with baseline Anti-Hypertensive medication intake equal to 1 medication: 0.5%</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9 Month Anti-hypertensive Medication In-take, 2 Medications</title>
        <description>Number of Anti-Hypertensive Medications taken-baseline compared to follow up, Per Subject Analysis (Intent-to-Treat Population)), reported as the percentage of participants using the number of medications indicated.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
        <time_frame>9 months</time_frame>
        <population>Patients with baseline Anti-Hypertensive medication intake equal to 2 medications: 29.2%</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>9 Month Anti-hypertensive Medication In-take, 2 Medications</title>
          <description>Number of Anti-Hypertensive Medications taken-baseline compared to follow up, Per Subject Analysis (Intent-to-Treat Population)), reported as the percentage of participants using the number of medications indicated.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
          <population>Patients with baseline Anti-Hypertensive medication intake equal to 2 medications: 29.2%</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9 Month Anti-hypertensive Medication In-take, 3 Medications</title>
        <description>Number of Anti-Hypertensive Medications taken-baseline compared to follow up, Per Subject Analysis (Intent-to-Treat Population)), reported as the percentage of participants using the number of medications indicated.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
        <time_frame>9 months</time_frame>
        <population>Patients with baseline Anti-Hypertensive medication intake equal to 3 Medications: 30.7%</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>9 Month Anti-hypertensive Medication In-take, 3 Medications</title>
          <description>Number of Anti-Hypertensive Medications taken-baseline compared to follow up, Per Subject Analysis (Intent-to-Treat Population)), reported as the percentage of participants using the number of medications indicated.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
          <population>Patients with baseline Anti-Hypertensive medication intake equal to 3 Medications: 30.7%</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9 mo in Anti-hypertensive Medication In-take, â‰¥ 4 Medications</title>
        <description>Number of Anti-Hypertensive Medications taken at follow up compared to baseline, Per Subject Analysis (Intent-to-Treat Population)), reported as the percentage of participants using the number of medications indicated.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
        <time_frame>9 months</time_frame>
        <population>Patients with baseline Anti-Hypertensive medication intake equal to or greater than 4 Medications: 39.6%</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>9 mo in Anti-hypertensive Medication In-take, â‰¥ 4 Medications</title>
          <description>Number of Anti-Hypertensive Medications taken at follow up compared to baseline, Per Subject Analysis (Intent-to-Treat Population)), reported as the percentage of participants using the number of medications indicated.
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
          <population>Patients with baseline Anti-Hypertensive medication intake equal to or greater than 4 Medications: 39.6%</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function (Measured by sCr)</title>
        <description>sCR= Serum Creatinine, per subject analysis. ITT. Renal function (measured by sCr) @ baseline: 1.2mg/dL (1.2, 1.3).
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
        <time_frame>9 months</time_frame>
        <population>Subject total reflects those who were evaluable at the time of analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RX Herculink Elite</title>
            <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function (Measured by sCr)</title>
          <description>sCR= Serum Creatinine, per subject analysis. ITT. Renal function (measured by sCr) @ baseline: 1.2mg/dL (1.2, 1.3).
The analysis population at clinical follow-up visits may have changed due to early termination from the study by the patient or physician.</description>
          <population>Subject total reflects those who were evaluable at the time of analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.6" lower_limit="1.2" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Post-procedure through 312 days</time_frame>
      <desc>Organ systems designations were chosen to match Abbott Categories coding as closely as possible and may differ from other coding systems.</desc>
      <group_list>
        <group group_id="E1">
          <title>RX Herculink Elite</title>
          <description>To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Abbott Categories</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Dyscrasia</sub_title>
                <description>Anemia</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>GI Bleed</sub_title>
                <description>Non-Access Site Bleeding</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Bleed</sub_title>
                <description>Non-Access Site Bleeding</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Cardiac/Hemodynamic">Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <description>Cardiac/Hemodynamic</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Arrhythmias (Bradycardia &amp; Tachycardia)</sub_title>
                <description>Cardiac/Hemodynamic</description>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <description>Cardiac/Hemodynamic</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <description>Cardiac/Hemodynamic</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Cardiac/Hemodynamic</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <description>Cardiac/Hemodynamic</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hypertension Exacerbation</sub_title>
                <description>Cardiac/Hemodynamic</description>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Cardiac/Hemodynamic</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pacemaker Issue</sub_title>
                <description>Cardiac/Hemodynamic</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Unstable Angina</sub_title>
                <description>Cardiac/Hemodynamic</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>Gastrointestinal</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Gastrointestinal</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Digestive Disorder</sub_title>
                <description>Gastrointestinal</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <description>Gastrointestinal</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Gastrointestinal</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pyloric Channel Ulcer</sub_title>
                <description>Gastrointestinal</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Gastrointestinal</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Edema (Non Pulmonary)</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Joint Pain</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Joint/Bone</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Lightheadedness/Dizziness</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Medication Side Effect</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Vision Disturbance</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Weight Gain/Loss</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Joint/Bone</sub_title>
                <description>Infection</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Viral, Bacterial and Fungal Infections</sub_title>
                <description>Infection</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Access site complication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte Imbalance</sub_title>
                <description>Metabolic</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <description>Neurological</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Stroke/Cerebral Vascular Accident</sub_title>
                <description>Neurological</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <description>Neurological</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine Increase</sub_title>
                <description>Renal</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Cysts/Stones</sub_title>
                <description>Renal</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Insufficiency</sub_title>
                <description>Renal</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <description>Renal</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Pulmonary/Respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <description>Pulmonary/Respiratory</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Pulmonary/Respiratory</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <description>Pulmonary/Respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <description>Pulmonary/Respiratory</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <description>Pulmonary/Respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <description>Pulmonary/Respiratory</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Claudication</sub_title>
                <description>Vascular</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Ischemia</sub_title>
                <description>Vascular</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <description>Vascular</description>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <description>Vascular</description>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <description>Vascular</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Total Occlusion</sub_title>
                <description>Vascular</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Abbott Categories</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertention Exacerbation</sub_title>
                <description>Cardiac/Hemodynamic</description>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive Disorder</sub_title>
                <description>Gastrointestinal</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Gastrointestinal</description>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Fatigue/Weakness</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Joint Pain</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Lightheadedness/Dizziness</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Miscellaneous</description>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Infection</description>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Access Site Complication</description>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ellen Travis</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>408-845-1512</phone>
      <email>Ellen.Travis@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

